AI in Recruitment: What It Can and Cannot Replace in High-Stakes Life Sciences Hiring
The Life Sciences sector—encompassing pharmaceuticals, biotechnology, and medical device manufacturing—operates on a razor-thin margin for error. In this industry, a “bad hire” isn’t just a budgetary line item; it can derail a clinical trial, compromise regulatory compliance, or delay a life-saving therapy from reaching the market. As Artificial Intelligence (AI) permeates the human resources landscape, […]
DNA First: Why Organisational Values Should Drive Every Hiring Decision
In the high-stakes race for top talent, companies often fall into the “competency trap.” We scour resumes for prestigious degrees, technical certifications, and years of experience in specific niches. We prioritize what a candidate can do over who they are. However, as many leaders eventually discover—often the hard way—a brilliant software engineer who doesn’t collaborate, or a high-performing sales executive […]
The Rise of the Fractional Executive in Biotech: Stopgap or Strategic Advantage?
The biotech industry is currently navigating a “perfect storm” of economic volatility. On one side, the scientific frontier is expanding rapidly with breakthroughs in CRISPR, mRNA, and AI-driven drug discovery. On the other, the capital markets have become increasingly selective. For many emerging startups, this has created a precarious gap: the need for world-class leadership […]
What Great Life Sciences Leaders Have in Common — And How to Hire for It
The life sciences sector is currently navigating a period of profound transformation. From the rapid integration of AI in drug discovery to the shifting landscape of global regulatory compliance, the stakes have never been higher. In this high-pressure environment, the difference between a breakthrough therapy and a clinical failure often comes down to one factor: leadership. […]
Building Quality Functions From Scratch: What Early-Stage Biotech Gets Wrong About QA Hiring
In the adrenaline-fueled trajectory of an early-stage biotech, the focus is almost always on the “three pillars” of survival: clinical data, fundraising, and intellectual property. Quality Assurance (QA) is frequently treated as a fourth, distant pillar—a “check-the-box” requirement that can be deferred until a lead candidate approaches the clinic. This is the first, and perhaps […]
The New Digital Front Line: Cyber Warfare and the US Healthcare Infrastructure
For decades, the “front lines” of war were physical—geographic borders defined by boots on the ground. But in March 2026, for the US healthcare and life sciences sector, the front line has moved to the server room. While kinetic conflict unfolds thousands of miles away, a different kind of war is being waged against US-based medical […]
Why Most First Launches Fail
A first commercial launch is one of the most unforgiving transitions in life sciences. The company moves from proving a molecule’s promise to proving an enterprise can deliver—reliably, compliantly, and at scale. Most first launches do not “fail” because the product is weak. They fail because leadership underestimates the integrated complexity of commercialization: manufacturing and […]
Why Quality & CMC Are Now CEO-Critical Functions
For years, many life sciences leaders treated Quality and CMC (Chemistry, Manufacturing, and Controls) as necessary enablers: essential for compliance, but fundamentally operational. That framing no longer reflects reality. Today, Quality and CMC are board-level risk and value drivers. They determine how quickly you can progress from clinical promise to commercial reliability, how resilient your […]
The Hidden Manufacturing Talent Crisis
The Hidden Manufacturing Talent Crisis In life sciences, manufacturing has quietly become one of the most consequential constraints on growth. Not because companies lack capital, assets, or demand—but because they lack people with the right operational “scar tissue” to scale complex products under GMP conditions. This is the hidden manufacturing talent crisis: the sector’s manufacturing […]
What VC-Backed Biotech Boards Expect from Leadership
In VC-backed biotech, boards are not simply governance bodies—they are active stakeholders underwriting scientific risk with time-bound capital. Their expectations of leadership are therefore different from those in large pharma and meaningfully more demanding than many first-time CEOs anticipate. Boards are betting on a company’s ability to convert uncertainty into value through credible plans, disciplined […]